About Anima Biotech
Anima Biotech is pioneering Translation Control Therapeutics, a novel approach for the discovery of small molecules that selectively control mRNA translation as a new strategy against undruggable proteins.
Our platform addresses the widest range of diseases including where proteins are overexpressed, underexpressed or mutated.
With our proprietary technology that emits light pulses from ribosomes, we identify drug candidates that selectively decrease or increase the translation of proteins and elucidate their mechanisms of action in a new target space.
Our pipeline includes programs in Fibrosis (tissue selective Collagen I translation inhibitors), Oncology (selective translation inhibitors of c-Myc and K-Ras), RSV (viral translation inhibitors) and Huntington's disease (selective inhibition of the mutant mHTT) extended to a broader approach toward Repeat Associated Diseases (translation malfunctions).
Anima’s Translation Control Therapeutics platform is strategically designed for partnering with Pharma. The power of Anima’s approach was solidified with a $1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets in Neuroscience. Anima’s technology has been further validated by 7 patents, 15 peer reviewed publications and 17 scientific collaborations.